FORM PTO-1449
SECOND SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1488.131000C/EKS/EJHAPPLICATION NO.
10/648,825APPLICANT
Ni et al.FILING DATE
August 27, 2003GROUP
1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
U	AK1	6,072,047	06/06/2000	Rauch et al.			06/26/1997

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR		
	AS		
	AT		

EXAMINER

Chen Ky

DATE, CONSIDERED

9/4/06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

THIRD SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1488.131000C/EKS/EJHAPPLICATION NO.
10/648,825APPLICANT
Ni et al.FILING DATE
August 27, 2003GROUP
1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
<i>C</i>	AA2	6,313,269 B1	11/06/2001	Deen et al.			06/15/1999
<i>C</i>	AB2	6,342,369 B1	01/29/2002	Ashkenazi			05/14/1998
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR		
	AS		
	AT		

EXAMINER

Cla K

DATE CONSIDERED

4/4/06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449 FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1488.131000C/EKS/EJH	APPLICATION NO. 10/648,825
	APPLICANT Ni et al.	
	FILING DATE August 27, 2003	GROUP 1646

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
CA	AN3	WO 98/46643 A1	10/22/1998	WIPO			Yes No
	AO3	WO 98/51793 A1	11/19/1998	WIPO			Yes No
CR	AP3	WO 99/00423 A1	01/07/1999	WIPO			Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR		
	AS		
CK	AT	2	Beutler, B., and Cerami, A., "Tumor Necrosis, Cachexia, Shock, and Inflammation: A Common Mediator," Ann. Rev. Biochem. 57:505-518, Annual Reviews Inc. (1988)

EXAMINER 	DATE CONSIDERED 9/4/02
--------------	---------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1488.131000C/EKS/EJH	APPLICATION NO. 10/648,825
	APPLICANT Ni et al.	
	FILING DATE August 27, 2003	GROUP 1646

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
CR	AR	8	Fiers, W., "Tumor necrosis factor. Characterization at the molecular, cellular and in vivo level," <i>FEBS Lett.</i> 285:199-212, Elsevier Science B.V. (1991)
	AS	8	Goeddel, D.V., et al., "Tumor Necrosis Factors: Gene Structure and Biological Activities," <i>Cold Spring Harb. Symp. Quant. Biol.</i> 51(Pt. 1):597-609, Cold Spring Harbor Laboratory Press (1986)
CR	AT	8	Golstein, P., "Cell death: TRAIL and its receptors," <i>Curr. Biol.</i> 7:R750-R753, Current Biology Ltd. (December 1997)

EXAMINER <i>Clair B.</i>	DATE CONSIDERED 4/4/06
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	

FORM PTO-1449 FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1488.131000C/EKS/EJH	APPLICATION NO. 10/648,825
	APPLICANT Ni et al.	
	FILING DATE August 27, 2003	GROUP 1646

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
ch	AR	2	Gruss, H.-J., and Dower, S.K., "Tumor Necrosis Factor Ligand Superfamily: Involvement in the Pathology of Malignant Lymphomas," <i>Blood</i> 85:3378-3404, The American Society of Hematology (1995)
↓	AS	2	Locksley, R.M., et al., "The TNF and TNF Receptor Superfamilies: Integrating Mammalian Biology," <i>Cell</i> 104:487-501, Cell Press (February 2001)
ce	AT	2	Nagata, S., "Apoptosis by Death Factor," <i>Cell</i> 88:355-365, Cell Press (February 1997)



EXAMINER	<i>Chen K</i>	DATE CONSIDERED	7/4/06
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			


FORM PTO-1449 FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1488.131000C/EKS/EJH	APPLICATION NO. 10/648,825
	APPLICANT Ni et al.	
	FILING DATE August 27, 2003	GROUP 1646

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	10	Old, L.J., "Tumor Necrosis Factor," <i>Scientific American</i> , pp. 59-75, Scientific American, Inc. (May 1988)
	AS	10	Wallach, D., "TNF Ligand and TNF/NGF Receptor Families," in <i>Cytokine Reference. A compendium of cytokines and other mediators of host defense</i> , Oppenheim, J.J., et al., eds., Academic Press, Inc., San Diego, CA, pp. 377-411 (August 2000)
	AT		

EXAMINER 	DATE CONSIDERED 4/4/06
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	



FORM PTO-1449 FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1488.131000C/EKS/EJH	APPLICATION NO. 10/648,825
	APPLICANT Ni et al.	
	FILING DATE August 27, 2003	GROUP 1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM3	WO 99/02653	01/21/1999	WIPO			Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR		
	AS		
	AT	5	Chaudhary, P.M., et al., "Death Receptor 5, a New Member of the TNFR Family, and DR4 Induce FADD-Dependent Apoptosis and Activate the NF- κ B Pathway," <i>Immunity</i> 7:821-830, Cell Press (December 1997).

EXAMINER 	DATE CONSIDERED 4/4/06
--------------	---------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

FIRST SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1488.131000C/EKS/EJHAPPLICATION NO.
10/648,825APPLICANT
Ni et al.FILING DATE
August 27, 2003GROUP
1646




U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	6	Marsters, S.A., et al., "A novel receptor for APO2L/TRAIL contains a truncated death domain," Curr. Biol. 7:1003-1006, Current Biology Ltd. (December 1997).
	AS	6	Rieger, J., et al., "APO2 ligand: a novel lethal weapon against malignant glioma?" FEBS Lett. 427:124-128, Federation of European Biochemical Societies (May 1998).
	AT	6	Schneider, P., et al., "TRAIL Receptors 1 (DR4) and 2 (DR5) Signal FADD-Dependent Apoptosis and Activate NF-κB," Immunity 7:831-836, Cell Press (December 1997).

EXAMINER



DATE CONSIDERED

4/4/06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1488.131000C/EKS/EJH	APPLICATION NO. 10/648,825
	APPLICANT Ni et al.	
	FILING DATE August 27, 2003	GROUP 1646

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
CA	AR	1	Sheikh, S.M., et al., "p53-dependent and -independent Regulation of the Death Receptor KILLER/DR5 Gene Expression in Response to Genotoxic Stress and Tumor Necrosis Factor α ," <i>Cancer Res.</i> 58:1593-1598, American Association for Cancer Research (April 1998).
a	AS	1	Zamai, L., et al., "Natural killer (NK) Cell-mediated Cytotoxicity: Differential Use of TRAIL and Fas Ligand by Immature and Mature Primary Human NK Cells," <i>J. Exp. Med.</i> 188:2375-2380, Rockefeller University Press (December 1998).
	AT		

EXAMINER	<i>Chen</i>	DATE CONSIDERED	4/4/06
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1488.131000C/EKS/EJHAPPLICATION NO.
10/648,825APPLICANT
Ni et al.FILING DATE
August 27, 2003GROUP
1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
CA	AA1	4,002,531	01/11/1977	Royer	X	X	01/22/1976
	AB1	4,946,778	08/07/1990	Ladner et al.			01/19/1989
	AC1	5,349,053	09/20/1994	Landolfi			06/10/1993
	AD1	5,447,851	09/05/1995	Beutler et al.			04/02/1992
	AE1	5,478,925	12/26/1995	Wallach et al.			08/07/1992
	AF1	5,530,101	06/25/1996	Queen et al.			12/19/1990
	AG1	5,565,332	10/15/1996	Hoogenboom et al.			09/23/1994
	AH1	5,643,575	07/01/1997	Martinez et al.			10/27/1993
	AI1	5,763,223	06/09/1998	Wiley et al.			06/25/1996
CA	AJ1	5,807,715	09/15/1998	Morrison et al.			06/27/1994
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
CA	AL1	EP 0 239 400	09/30/1987	Europe	X	X	Yes No
	AM1	EP 0 401 384	12/12/1990	Europe			Yes No
	AN1	WO 91/06570	05/16/1991	WIPO			Yes No
	AO1	WO 91/09967	07/11/1991	WIPO			Yes No
CA	AP1	CA 2045869	12/29/1991	Canada			Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

CA	AR	1	Uhlén, M., et al., "Fusion proteins in biotechnology," Curr. Opin. Biotechnol. 3:363-369, Current Biology Ltd. (1992).
	AS	1	Chinnaiyan, A.M., et al., "Signal Transduction by DR3, a Death Domain-Containing Receptor Related to TNFR-1 and CD95," Science 274:990-992, American Association for the Advancement of Science (November 1996).
CA	AT	1	Delgado, C., et al., "The Uses and Properties of PEG-Linked Proteins," Crit. Rev. Ther. Drug Carrier Sys. 9:249-304, CRC Press (1992).

EXAMINER

DATE CONSIDERED

4/4/02

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 1488.131000C/EKS/EJH	APPLICATION NO. 10/648,825
	APPLICANT Ni et al.	
	FILING DATE August 27, 2003	GROUP 1646

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
<i>Ch</i>	AL2	EP 0 510 691	10/28/1992	Europe			Yes No
	AM2	WO 94/01548	01/20/1994	WIPO			Yes No
	AN2	WO 95/06058	03/02/1995	WIPO			Yes No
<i>N</i>	AO2	WO 98/32856	07/30/1998	WIPO			Yes No
<i>Ch</i>	AP2	WO 98/35986	08/20/1998	WIPO			Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
<i>Ch</i>	AR	2	NCBI Entrez, GenBank Report, Accession No. Z66083, "H. sapiens CpG island DNA genomic MseI fragment," clone 75a7, reverse read cpg75a7.rtl1a, accessed 12/1998, Oct. 23, 1995.
	AS	2	NICBI Entrez, GenBank Report, Accession No. AA232440 (Feb. 28, 1997).
<i>Ch</i>	AT	2	NCBI Entrez, GenBank Report, Accession No. AA223122 (Feb 19, 1997).

EXAMINER <i>Ch</i>	DATE CONSIDERED <i>4/4/04</i>
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 1488.131000C/EKS/EJH	APPLICATION NO. 10/648,825
	APPLICANT Ni et al.	
	FILING DATE August 27, 2003	GROUP 1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
<i>CL</i>	AL3	EP 0 870 827 A2	10/14/1998	Europe			Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

<i>CL</i>	AR	3	Huston, J.S., et al., "Protein Engineering of Single-Chain Fv Analogs and Fusion Proteins," <i>Methods in Enzymol.</i> 203:46-88, Academic Press (1991).
<i>1</i>	AS	3	Morpurgo, M., et al., "Covalent Modification of Mushroom Tyrosinase with Different Amphiphilic Polymers for Pharmaceutical and Biocatalysis Applications," <i>Appl. Biochem. Biotechnol.</i> 56:59-72, Humana Press (January 1996).
<i>2</i>	AT	3	Morrison, S.L., "Transfectionomas Provide Novel Chimeric Antibodies," <i>Science</i> 229:1202-1207, American Association for the Advancement of Science (1985).

EXAMINER <i>Clarke</i>	DATE CONSIDERED <i>4/4/04</i>
------------------------	-------------------------------




EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.


FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 1488.131000C/EKS/EJH	APPLICATION NO. 10/648,825
	APPLICANT Ni et al.	
	FILING DATE August 27, 2003	GROUP 1646

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>4</u>	Pan, G., et al., "The Receptor for the Cytotoxic Ligand TRAIL," <i>Science</i> 276:111-113, American Association for the Advancement of Science (April 1997).
	AS	<u>4</u>	Pan, G., et al., "An Antagonist Decoy Receptor and a Death Domain-Containing Receptor for TRAIL," <i>Science</i> 277:815-818, American Association for the Advancement of Science (August 1997).
	AT	<u>4</u>	Roguska, M.A., et al., "Humanization of murine monoclonal antibodies through variable domain resurfacing," <i>Proc. Natl. Acad. Sci.</i> 91:969-973, National Academy of Sciences (1994).

EXAMINER 	DATE CONSIDERED 4/4/06
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1488.131000C/EKS/EJHAPPLICATION NO.
10/648,825APPLICANT
Ni et al.FILING DATE
August 27, 2003GROUP
1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

<i>h</i>	AR	<u>5</u>	Sheridan, J.P., et al., "Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors," <i>Science</i> 277:818-821, American Association for the Advancement of Science (August 1997).
<i>h</i>	AS	<u>5</u>	Wiley, et al., Identification and characterization of a new member of the TNF family that induces apoptosis," <i>Immunity</i> 3:673-682, Cell Press (1995).
	AT		


EXAMINER

Clair K

DATE CONSIDERED

7/14/06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

FIFTH SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1488.131000C/EKS/EJHAPPLICATION NO.
10/648,825APPLICANT
Ni et al.FILING DATE
August 27, 2003GROUP
1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
<i>u</i>	AC 2	6,569,642 B1	05/27/ 2003	Rauch et al.	435	69.1	03/27/2000
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR		
	AS		
<i>u</i>	AT	10	Brojatsch, J., et al., "CAR1, a TNFR-Related Protein, Is a Cellular Receptor for Cytopathic Avian Leukosis-Sarcoma Viruses and Mediates Apoptosis," <i>Cell</i> 87:845-855, Cell Press (November 1996)

EXAMINER

Clark

DATE CONSIDERED

4/4/06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

FIFTH SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1488.131000C/EKS/EJHAPPLICATION NO.
10/648,825APPLICANT
Ni *et al.*FILING DATE
August 27, 2003GROUP
1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

<i>ce</i>	AR	11	Chapman, B.S., "A region of the 75 kDa neurotrophin receptor homologous to the death domains of TNFR-I and Fas," <i>FEBS Lett.</i> 374:216-220, Elsevier (1995)
<i>ce</i>	AS	11	Rabizadeh, S., <i>et al.</i> , "Induction of Apoptosis by the Low-Affinity NGF Receptor," <i>Science</i> 261:345-348, American Association for the Advancement of Science (1993)
<i>ce</i>	AT	11	Tartaglia, L.A., <i>et al.</i> , "A Novel Domain within the 55 kd TNF Receptor Signals Cell Death," <i>Cell</i> 74:845-853, Cell Press (1993)

EXAMINER

Chir K

DATE CONSIDERED

7/4/06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 FIFTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1488.131000C/EKS/EJH	APPLICATION NO. 10/648,825
	APPLICANT Ni <i>et al.</i>	
	FILING DATE August 27, 2003	GROUP 1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

ck	AR	12	— DO NOT PRINT — Statutory Declaration of Avi J. Ashkenazi, signed March 14, 2003
ck	AS	12	— DO NOT PRINT — Curriculum vitae of Avi Ashkenazi
ck	AT	12	Copy of provisional U.S. application 60/040,846, inventor Ni <i>et al.</i> , filed March 17, 1997

EXAMINER <i>Chari K</i>	DATE CONSIDERED 9/4/06
----------------------------	---------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 FIFTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1488.131000C/EKS/EJH	APPLICATION NO. 10/648,825
	APPLICANT Ni <i>et al.</i>	
	FILING DATE August 27, 2003	GROUP 1646

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

ce	AR	13	Copy of provisional U.S. application 60/054,021, inventor Ni <i>et al.</i> , filed July 29, 1997
u	AS	13	<p align="center">— DO NOT PRINT —</p> Copy of U.S. application 08/857,216, inventor Ashkenazi, filed May 15, 1997
	AT	13	<p align="center">— DO NOT PRINT —</p> Statement of Grounds and Particulars filed in opposition to Human Genome Sciences, Inc., Australian Patent Application 747635 (67635/98) by Genentech, Inc.

EXAMINER <i>Clavin E</i>	DATE CONSIDERED 4/4/06
-----------------------------	---------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449 <u>SIXTH SUPPLEMENTAL</u> <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 1488.131000C/EKS/EJH	APPLICATION NO. 10/648,825
	APPLICANT Ni et al.	
	FILING DATE August 27, 2003	GROUP 1646

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
CK	AD 2	2002/0072091	06/13/2002	Ni et al.			06/06/2001
CA	AE 2	2002/0098550	07/25/2002	Ni et al.			12/07/2001
	AF	* DUPLICATE					
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

CA	AR	14	Tartaglia, L.A., et al., "The two different receptors for tumor necrosis factor mediate distinct cellular responses," <i>Proc. Natl. Acad. Sci. USA</i> 88:9292-9296, National Academy of Sciences (1991).
U	AS	14	Tartaglia, L.A., and Goeddel, D.V., "Tumor Necrosis Factor Receptor Signaling," <i>J. Biol. Chem.</i> 267:4304-4307, The American Society for Biochemistry and Molecular Biology, Inc. (1992).
CK	AT	14	Pending Non-Provisional United States Patent Application No. 09/042,583, Ni et al., filed March 17, 1998 (NOT PUBLISHED).

EXAMINER <i>Clark</i>	DATE CONSIDERED 4/4/06
--------------------------	---------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 SIXTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1488.131000C/EKS/EJH	APPLICATION NO. 10/648,825
	APPLICANT Ni et al.	
	FILING DATE August 27, 2003	GROUP 1646

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

<i>ck</i>	AR	15	Pending Non-Provisional United States Patent Application No. 09/565,009, Ni et al., filed May 4, 2000, (NOT PUBLISHED) now US Patent 6,872,568.
	AS	15	Pending Non-Provisional United States Patent Application No. not assigned, Ni et al., filed February 2, 2004 (NOT PUBLISHED)
<i>ck</i>	AT	15	DO NOT PRINT Pending Non-Provisional U.S. Patent Application No. 09/912,293, filed July 26, 2001, NOT PUBLISHED: pages 1-75 (pages 1 + 2 partially redacted); portion of Table 2; and SEQ ID NOs.: 7851 and 190763.

EXAMINER <i>Clair Ky</i>	DATE CONSIDERED 4/9/06
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	

FORM PTO-1449

JUL 23 2004

ATTY. DOCKET NO.
0488.131000C/EKS/EJH/M-M
FIRST NAMED INVENTOR
et al.APPLICATION NO.
10/648,825SEVENTH SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENTFILING DATE
August 27, 2003ART UNIT
1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
CU	AF2	2002/0098550	07/25/2002	Ni et al.	X	X	12/07/2001
	AG2	6,743,625	06/01/2004	Ni et al.			06/06/2001
	AH2	6,461,823	10/08/2002	Ni et al.			11/24/1999
	AI2	6,342,363	01/29/2002	Ni et al.			01/27/1998
Ca	AJ2	6,433,147	08/13/2002	Ni et al.			05/05/2000
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
CU	AL4	WO 98/41629 A2 & A3	09/24/1998	WIPO	X	X	Yes
	AM4	EP 1 181 319 A0	12/07/2000	Europe			No
	AN4	EP 1 192 185 A0	12/14/2000	Europe			Yes
	AO4	EP 1 287 035 A1	03/05/2003	Europe			No
Ca	AP						Yes
							No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

Ca	AR	16	Allison, J., et al., "Transgenic expression of CD95 ligand on islet β cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts," <i>Proc. Natl. Acad. Sci. USA</i> 94:3943-3947, National Academy Press (April 1997)
	AS	16	Allison, J., and Strasser, A., "Mechanisms of β cell death in diabetes: A minor role for CD95," <i>Proc. Natl. Acad. Sci. USA</i> 95:13818-13822, National Academy Press (November 1998)
Ca	AT	16	Bodmer, J.-L., et al., "TRAMP, a Novel Apoptosis-Mediating Receptor with Sequence Homology to Tumor Necrosis Factor Receptor 1 and Fas(Apo-1/CD95)," <i>Immunity</i> 6:79-88, Cell Press (January 1997)

EXAMINER

Clarke

DATE CONSIDERED

9/4/06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Page 2 of 18	
FORM PTO-1449	<div style="display: flex; justify-content: space-between;"> <div> <p>ATTY. DOCKET NO. G488.131000C/EKS/EJH/M-M</p> <p>FIRST NAMED INVENTOR Nij et al.</p> <p>FILING DATE August 27, 2003</p> </div> <div> <p>APPLICATION NO. 10/648,825</p> <p>ART UNIT 1646</p> </div> </div>
<p>SEVENTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</p>	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

CR	AR	17	Boldin, M.P., et al., "A Novel Protein That Interacts with the Death Domain of Fas/APO1 Contains a Sequence Motif Related to the Death Domain," <i>J. Biol. Chem.</i> 270:7795-7798, American Society for Biochemistry and Molecular Biology, Inc. (1995)
↓	AS	17	Chicheportiche, Y., et al., "TWEAK, a New Secreted Ligand in the Tumor Necrosis Factor Family That Weakly Induces Apoptosis," <i>J. Biol. Chem.</i> 272:32401-32410, American Society for Biochemistry and Molecular Biology, Inc. (December 1997)
↓	AT	17	Chinnaiyan, A.M., et al., "FADD, a Novel Death Domain-Containing Protein, Interacts with the Death Domain of Fas and Initiates Apoptosis," <i>Cell</i> 81:505-512, Cell Press (1995)

EXAMINER	DATE CONSIDERED
	<p>4/4/06</p>
<p>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.</p>	

FORM PTO-1449 SEVENTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1488.131000C/EKS/EJH/M-M	APPLICATION NO. 10/648,825
	FIRST NAMED INVENTOR Ni <i>et al.</i>	
	FILING DATE August 27, 2003	ART UNIT 1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

CA	AR	18	Clerici, M., <i>et al.</i> , "Type 1 and Type 2 Cytokines in HIV Infection - A Possible Role in Apoptosis and Disease Progression," <i>Ann. Med.</i> 29:185-188, Finnish Medical Society DUODECIM (June 1997)
	AS	18	Degli-Esposti, M.A., <i>et al.</i> , "Cloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor Family," <i>J. Exp. Med.</i> 186:1165-11170, Rockefeller University Press (October 1997)
a	AT	18	Degli-Esposti, M.A., <i>et al.</i> , "The Novel Receptor TRAIL-R4 Induces NF- κ B and Protects against TRAIL-Mediated Apoptosis, yet Retains an Incomplete Death Domain," <i>Immunity</i> 7:813-820, Cell Press (December 1997)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 SEVENTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1488.131000C/EKS/EJH/M-M	APPLICATION NO. 10/648,825
	FIRST NAMED INVENTOR Ni <i>et al.</i>	
	FILING DATE August 27, 2003	ART UNIT 1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

CL	AR	19	Duan, H. and Dixit, V.M., "RAIDD is a new 'death' adaptor molecule," <i>Nature</i> 385:86-89, Macmillan Publishers, Ltd. (January 1997)
I	AS	19	Frankfurt, O.S., <i>et al.</i> , "Protection from Apoptotic Cell Death by Interleukin-4 is Increased in Previously Treated Chronic Lymphocytic Leukemia Patients," <i>Leuk. Res.</i> 21:9-16, Elsevier Science, Ltd (January 1997)
2	AT	19	Gooch, J.L., <i>et al.</i> , "Interleukin 4 Inhibits Growth and Induces Apoptosis in Human Breast Cancer Cells," <i>Cancer Res.</i> 58:4199-4205, American Association for Cancer Research (September 1998)

EXAMINER <i>Chen</i>	DATE CONSIDERED 4/4/06
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	

FORM PTO-1449

SEVENTH SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1488.131000C/EKS/EJH/M-MAPPLICATION NO.
10/648,825FIRST NAMED INVENTOR
Ni *et al.*FILING DATE
August 27, 2003ART UNIT
1646


U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>20</u>	Grell, M., <i>et al.</i> , "Induction of cell death by tumour necrosis factor (TNF) receptor 2, CD40 and CD30: a role for TNF-R1 activation by endogenous membrane-anchored TNF," <i>EMBO J.</i> 18:3034-3043, Oxford University Press (June 1999)
	AS	<u>20</u>	Hardiman, G., <i>et al.</i> , "Genetic Structure and Chromosomal Mapping of MyD88," <i>Genomics</i> 45:332-339, Academic Press (October 1997)
	AT	<u>20</u>	Hildeman, D.A., <i>et al.</i> , "Activated T Cell Death In Vivo Mediated by Proapoptotic Bcl-2 Family Member Bim," <i>Immunity</i> 16:759-767, Cell Press (June 2002)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 SEVENTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1488.131000C/EKS/EJH/M-M	APPLICATION NO. 10/648,825
	FIRST NAMED INVENTOR Ni <i>et al.</i>	
	FILING DATE August 27, 2003	ART UNIT 1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

CK	AR	21	Hill, M.E., <i>et al.</i> , "Prognostic Significance of BCL-2 Expression and <i>bcl-2</i> Major Breakpoint Region Rearrangement in Diffuse Large Cell Non-Hodgkin's Lymphoma: A British National Lymphoma Investigation Study," <i>Blood</i> 88:1046-105, American Society of Hematology (August 1996)
	AS	21	Hofmann, K., and Bucher, P., "The CARD domain: a new apoptotic signalling motif," <i>Trends Biochem. Sci.</i> 22:155-156, Elsevier Science, Ltd. (May 1997)
2	AT	21	Horigome, A., <i>et al.</i> , "Tacrolimus-induced apoptosis and its prevention by interleukins in mitogen-activated human peripheral-blood mononuclear cells," <i>Immunopharmacology</i> 39:21-30, Elsevier Science B.V. (March 1998)

EXAMINER

C. Davis

DATE CONSIDERED

4/4/06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

SEVENTH SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1488.131000C/EKS/EJH/M-MAPPLICATION NO.
10/648,825FIRST NAMED INVENTOR
Ni *et al.*FILING DATE
August 27, 2003ART UNIT
1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

ck	AR	22	Hsu, H., <i>et al.</i> , "TRADD-TRAF2 and TRADD-FADD Interactions Define Two Distinct TNF Receptor 1 Signal Transduction Pathways," <i>Cell</i> 84:299-308, Cell Press (January 1996)
↑	AS	22	Huang, D.C.S., <i>et al.</i> , "Activation of Fas by FasL induces apoptosis by a mechanism that cannot be blocked by Bcl-2 or Bcl-x _L ," <i>Proc. Natl. Acad. Sci. USA</i> 96:14871-14876, National Academy Press (December 1999)
↓ a	AT	22	Huang, D.C.S., <i>et al.</i> , "Bcl-2, Bcl-x _L and adenovirus protein E1B19kD are functionally equivalent in their ability to inhibit cell death," <i>Oncogene</i> 14:405-414, Stockton Press (January 1997)

EXAMINER

DATE CONSIDERED

4/4/06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

SEVENTH SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1488.131000C/EKS/EJH/M-MAPPLICATION NO.
10/648,825FIRST NAMED INVENTOR
Ni *et al.*FILING DATE
August 27, 2003ART UNIT
1646




U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>23</u>	Irmier, M., <i>et al.</i> , "Inhibition of death receptor signals by cellular FLIP," <i>Nature</i> 388:190-195, Macmillan Publishers, Ltd. (July 1997)
	AS	<u>23</u>	Irmier, M., <i>et al.</i> , "Inhibition of death receptor signals by cellular FLIP," <i>Nature</i> 388:190-195, Macmillan Publishers, Ltd. (July 1997)
	AT	<u>23</u>	Karin, M., and Lin, A., "NF- κ B at the crossroads of life and death," <i>Nat. Immunol.</i> 3:221-227, Nature Publishing Group (March 2002)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

SEVENTH SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1488.131000C/EKS/EJH/M-MAPPLICATION NO.
10/648,825FIRST NAMED INVENTOR
Ni *et al.*FILING DATE
August 27, 2003ART UNIT
1646




U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						


FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>24</u>	Kelliher, M.A., <i>et al.</i> , "The Death Domain Kinase RIP Mediates the TNF-Induced NF- κ B Signal," <i>Immunity</i> 8:297-303, Cell Press (March 1998)
	AS	<u>24</u>	Lindner, H., <i>et al.</i> , "Peripheral Blood Mononuclear Cells Induce Programmed Cell Death in Human Endothelial Cells and May Prevent Repair: Role of Cytokines," <i>Blood</i> 89:1931-1938, American Society of Hematology (March 1997)
	AT	<u>24</u>	Lotem, J., and Sachs, L., "Hematopoietic Cytokines Inhibit Apoptosis Induced by Transforming Growth Factor β 1 and Cancer Chemotherapy Compounds in Myeloid Leukemic Cells," <i>Blood</i> 80:1750-1757, American Society of Hematology (1992)

EXAMINER



DATE CONSIDERED

4/4/06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 SEVENTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1488.131000C/EKS/EJH/M-M	APPLICATION NO. 10/648,825
	FIRST NAMED INVENTOR Ni <i>et al.</i>	
	FILING DATE August 27, 2003	ART UNIT 1646




U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						


FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>25</u>	Lotem, J., and Sachs, L., "Interferon- γ inhibits apoptosis induced by wild-type p53, cytotoxic anti-cancer agents and viability factor deprivation in myeloid cells," <i>Leukemia</i> 9:685-692, Stockton Press (1995)
	AS	<u>25</u>	MacFarlane, M., <i>et al.</i> , "Identification and Molecular Cloning of Two Novel Receptors for the Cytotoxic Ligand TRAIL," <i>J. Biol. Chem.</i> 272:25417-25420, American Society for Biochemistry and Molecular Biology, Inc. (October 1997)
	AT	<u>25</u>	Muzio, M., <i>et al.</i> , "FLICE, a Novel FADD-Homologous ICE/CED-3-like Protease, Is Recruited to the CD95 (Fas/APO-1) Death-Inducing Signaling Complex," <i>Cell</i> 85:817-827, Cell Press (June 1996)

EXAMINER



DATE CONSIDERED

4/14/06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

SEVENTH SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1488.131000C/EKS/EJH/M-M
FIRST NAMED INVENTOR
Ni *et al.*
FILING DATE
August 27, 2003APPLICATION NO.
10/648,825
ART UNIT
1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>26</u>	Muzio, M., <i>et al.</i> , "IRAK (Pelle) Family Member IRAK-2 and MyD88 as Proximal Mediators of IL-1 Signaling," <i>Science</i> 278:1612-1615, American Association for the Advancement of Science (November 1997)
	AS	<u>26</u>	Newton, K., <i>et al.</i> , "A dominant interfering mutant of FADD/MORT1 enhances deletion of autoreactive thymocytes and inhibits proliferation of mature T lymphocytes," <i>EMBO J.</i> 17:706-718, Oxford University Press (February 1998)
	AT	<u>26</u>	Newton, K., <i>et al.</i> , "FADD/MORT1 regulates the pre-TCR checkpoint and can function as a tumour suppressor," <i>EMBO J.</i> 19:931-941, Oxford University Press (March 2000)

EXAMINER

DATE CONSIDERED

4/4/06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 SEVENTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1488.131000C/EKS/EJH/M-M	APPLICATION NO. 10/648,825
	FIRST NAMED INVENTOR Ni <i>et al.</i>	
	FILING DATE August 27, 2003	ART UNIT 1646




U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>27</u>	Newton, K., <i>et al.</i> , "Effects of a dominant interfering mutant of FADD on signal transduction in activated T cells," <i>Curr. Biol.</i> 11:273-276, Elsevier Science, Ltd. (February 2001)
	AS	<u>27</u>	Newton, K., and Strasser, A., "Ionizing Radiation and Chemotherapeutic Drugs Induce Apoptosis in Lymphocytes in the Absence of Fas or FACC/MORT1 Signaling: Implications for Cancer Therapy," <i>J. Exp. Med.</i> 191:195-200, Rockefeller University Press (January 2000)
	AT	<u>27</u>	O'Conner, L., <i>et al.</i> , "Fas, p53, and Apoptosis," <i>Science</i> 284:1431b, American Association for the Advancement of Science (May 1999)

EXAMINER



DATE CONSIDERED

9/4/06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 SEVENTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1488.131000C/EKS/EJH/M-M	APPLICATION NO. 10/648,825
	FIRST NAMED INVENTOR Ni <i>et al.</i>	
	FILING DATE August 27, 2003	ART UNIT 1646




U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>28</u>	O'Conner, L., <i>et al.</i> , "CD95 (Fas/APO-1) and p53 Signal Apoptosis Independently in Diverse Cell Types," <i>Cancer Res.</i> 60:1217-1220, American Association for Cancer Research (March 2000)
	AS	<u>28</u>	Odaka, C., <i>et al.</i> , "Immunosuppressant deoxyspergualin induces apoptotic cell death in dividing cells," <i>Immunol.</i> 95:370-376, Blackwell Science, Ltd. (November 1998)
	AT	<u>28</u>	Pan, G., <i>et al.</i> , "TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling," <i>FEBS Lett.</i> 424:41-45, Elsevier Science B.V. (March 1998)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 SEVENTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1488.131000C/EKS/EJH/M-M	APPLICATION NO. 10/648,825
	FIRST NAMED INVENTOR Ni <i>et al.</i>	
	FILING DATE August 27, 2003	ART UNIT 1646




U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>29</u>	Screaton, G.R., <i>et al.</i> , "LARD: A new lymphoid-specific death domain containing receptor regulated by alternative pre-mRNA splicing," <i>Proc. Natl. Acad. Sci. USA</i> 94:4615-4619, National Academy Press (April 1997)
	AS	<u>29</u>	Simonitsch, I., and Krupitza, G., "Autocrine self-elimination of cultured ovarian cancer cells by tumour necrosis factor α (TNF- α)," <i>Br. J. Cancer</i> 78:862-870, Nature Publishing Group on behalf of Cancer Research, UK (October 1998)
	AT	<u>29</u>	Smith, K.G.C., <i>et al.</i> , "CrmA expression in T lymphocytes of transgenic mice inhibits CD95 (Fas/APO-1)-transduced apoptosis, but does not cause lymphadenopathy or autoimmune disease," <i>EMBO J.</i> 15:5167-5176, Oxford University Press (October 1996)

EXAMINER



DATE CONSIDERED

4/4/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 SEVENTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1488.131000C/EKS/EJH/M-M	APPLICATION NO. 10/648,825
	FIRST NAMED INVENTOR Ni <i>et al.</i>	
	FILING DATE August 27, 2003	ART UNIT 1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	30	Strasser, A., <i>et al.</i> , "Bcl-2 and Fas/APO-1 regulate distinct pathways to lymphocyte apoptosis," <i>EMBO J.</i> 14:6136-1647, Oxford University Press (1995)
AS	30	Thome, M., <i>et al.</i> , "Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors," <i>Nature</i> 386:517-521, Macmillan Publishers, Ltd. (April 1997)
AT	30	Villunger, A., <i>et al.</i> , "Fas Ligand, Bcl-2, Granulocyte Colony-Stimulating Factor, and p38 Mitogen-activated Protein Kinase: Regulators of Distinct Cell Death and Survival Pathways in Granulocytes," <i>J. Exp. Med.</i> 192:647-657, Rockefeller University Press (September 2000)

EXAMINER	DATE CONSIDERED
<i>[Signature]</i>	9/4/06
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	

FORM PTO-1449 SEVENTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1488.131000C/EKS/EJH/M-M	APPLICATION NO. 10/648,825
	FIRST NAMED INVENTOR Ni <i>et al.</i>	
	FILING DATE August 27, 2003	ART UNIT 1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

ck	AR	31	Villunger, A., <i>et al.</i> , "Fas Ligand-Induced c-Jun Kinase Activation in Lymphoid Cells Requires Extensive Receptor Aggregation But Is Independent of DAXX, and Fas-Mediated Cell Death Does Not Involve DAXX, RIP, or RAIDD," <i>J. Immunol.</i> 165:1337-1343, American Association of Immunologists (August 2000)
l	AS	31	Walczak, H., <i>et al.</i> , "TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL," <i>EMBO J.</i> 16:5386-5397, Oxford University Press (September 1997)
a	AT	31	Watanabe-Fukunaga, R., <i>et al.</i> , "Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis," <i>Nature</i> 356:314-317, Macmillan Publishers, Ltd. (1992)

EXAMINER <i>Chen K</i>	DATE CONSIDERED 4/4/06
------------------------	---------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 SEVENTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1488.131000C/EKS/EJH/M-M	APPLICATION NO. 10/648,825
	FIRST NAMED INVENTOR Ni <i>et al.</i>	
	FILING DATE August 27, 2003	ART UNIT 1646




U.S. PATENT DOCUMENTS


EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	32	Wong, B.B., <i>et al.</i> , "TRANCE Is a Novel Ligand of the Tumor Necrosis Factor Receptor Family That Activates c-Jun N-terminal Kinase in T Cells," <i>J. Biol. Chem.</i> 272:25190-25194, American Society for Biochemistry and Molecular Biology, Inc. (October 1997)
	AS	32	Yoshida, T., <i>et al.</i> , "Rapid B cell apoptosis induced by antigen receptor ligation does not require Fas (CD95/APO-1), the adaptor protein FADD/MORT1 or CrmA-sensitive caspases but is defective in both MRL-+/+ and MRL-lpr/lpr mice," <i>Int. Immunol.</i> 12:517-526, Japanese Society for Immunology (April 2000)
	AT	32	Zou, W., <i>et al.</i> , "Administration of Interleukin 13 to Simian Immunodeficiency Virus-Infected Macaques: Induction of Intestinal Epithelial Atrophy," <i>AIDS Res Hum Retroviruses</i> 14:775-793, Mary Ann Liebert, Inc. (June 1998)

EXAMINER 	DATE CONSIDERED 4/4/06
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	

FORM PTO-1449 SEVENTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1488.131000C/EKS/EJH/M-M	APPLICATION NO. 10/648,825
	FIRST NAMED INVENTOR Ni et al.	
	FILING DATE August 27, 2003	ART UNIT 1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	33	European Search Report for European Application No. EP 00 93 0329 mailed on February 6, 2004, Munich, Germany				
	AS	33	Co-Pending U.S. Patent Application No. 10/774,622, Ni et al., filed February 10, 2004, now (NOT PUBLISHED) U.S. Published Patent Application No. 2004/0141952				
	AT	33	Co-Pending U.S. Patent Application No. 10/005,842, Ni et al., filed December 7, 2001, now U.S. Published Patent Application No. 2002/0098550 (Document AE2) DUPLICATE →				

EXAMINER 	DATE CONSIDERED 4/14/06
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	



FORM PTO-1449

EIGHTH SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1488.131000C/EKS/EJH/M-MAPPLICATION NO.
10/648,825FIRST NAMED INVENTOR
Ni et al.FILING DATE
August 27, 2003ART UNIT
1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

cl	AR	34	Australian Opposition Document, EVIDENCE IN SUPPORT: Statutory Declaration of Andreas Strasser dated 7 April 2005 together with Exhibits AS-10 to AS-23, submitted by Genentech, Inc. in the Opposition to Australian Patent Application 747635 (67635/98), 467 pages (April 7, 2005)
	AS	34	Australian Opposition Document, EVIDENCE IN SUPPORT: Statutory Declaration of David Vaux dated 12 April 2005 together with Exhibits DLV-8 to DLV-20, submitted by Genentech, Inc. in the Opposition to Australian Patent Application 747635 (67635/98), 412 pages (April 12, 2005)
ca	AT	34	Australian Opposition Document, EVIDENCE IN SUPPORT: Statutory Declaration of Simon Tout dated 14 April 2005 together with Exhibits SDT-1 to SDT-3, submitted by Genentech, Inc. in the Opposition to Australian Patent Application 747635 (67635/98), 328 pages (April 14, 2005)

EXAMINER

Chen K

DATE CONSIDERED

9/4/06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

A circular stamp from the Office of Intellectual Property (OIP). The text "OIP" is at the top, "INSP" is at the top right, "NOV 04 2005" is in the center, and "PATENT & TRADEMARK OFFICE" is at the bottom.[illegible]

Examiner Signature		Date Considered	4/4/06
-----------------------	---	--------------------	--------

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.